Related Experiment Video
Updated: May 25, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Immunotherapy for the treatment of glioblastoma
Alissa A Thomas1, Marc S Ernstoff, Camilo E Fadul
1Department of Neurology, Dartmouth Medical School and Dartmouth-Hitchcock Medical Center, Lebanon, NH.
Abstract:
Glioblastoma, the most aggressive primary brain tumor, thrives in a microenvironment of relative immunosuppression within the relatively immune-privileged central nervous system. Despite treatments with surgery, radiation therapy, and chemotherapy, prognosis remains poor. The recent success of immunotherapy in the treatment of other cancers has renewed interest in vaccine therapy for the treatment of gliomas. In this article, we outline various immunotherapeutic strategies, review recent clinical trials data, and discuss the future of vaccine therapy for glioblastoma.

